Research shows that stomach cancer patients over 70 years old can safely receive FLOT chemotherapy before surgery if they’re carefully evaluated first, according to a 2025 international expert consensus. Gram Research analysis of 16 cancer specialists’ recommendations found that 66.3% of clinical statements reached agreement, including that patients need nutritional screening, genetic testing, and organ function checks before starting treatment, with dose adjustments rather than treatment skipping if side effects occur.
Doctors around the world now have clearer guidance on which stomach cancer patients should receive a strong four-drug combination called FLOT before surgery. According to Gram Research analysis, international cancer experts created new recommendations through a careful voting process, deciding that older patients and those with certain health conditions can safely receive this treatment if carefully evaluated first. The guidelines also emphasize the importance of making sure patients are well-nourished and physically prepared before starting treatment, and suggest doctors should adjust drug doses rather than skip doses when side effects occur. These new standards aim to help doctors make better decisions about who gets this life-saving treatment and how to support them through it.
Key Statistics
A 2025 modified Delphi consensus study of 16 international cancer experts reached agreement on 66.3% of clinical statements regarding FLOT chemotherapy selection and management for gastric cancer patients.
According to the 2025 expert consensus, patients over 70 years old should not be routinely excluded from perioperative FLOT treatment but require comprehensive health assessment before starting.
The 2025 international expert panel endorsed universal baseline nutritional screening for all gastric cancer patients receiving FLOT, with proactive intervention for malnourished patients before treatment begins.
A 2025 consensus of 16 cancer specialists supported dose modification over drug omission for managing FLOT side effects, preserving treatment effectiveness while improving patient tolerability.
The Quick Take
- What they studied: Which stomach cancer patients should receive a powerful four-drug chemotherapy combination called FLOT before surgery, and how doctors should manage this treatment safely.
- Who participated: Sixteen international cancer experts from different specialties (surgeons, medical oncologists, nutritionists, and others) participated in a structured voting process conducted online between March and August 2025.
- Key finding: Experts reached agreement on 66.3% of clinical recommendations, including that patients over 70 years old should not be automatically excluded from FLOT treatment, but need thorough health evaluation first.
- What it means for you: If you or a loved one has resectable gastric or gastroesophageal junction cancer, doctors now have clearer, internationally agreed-upon standards for deciding if FLOT treatment is appropriate and how to manage it safely. However, individual decisions should always be made with your own medical team based on your specific health situation.
The Research Details
This study used a modified Delphi methodology, which is a structured way to build expert consensus. Sixteen international cancer specialists independently rated clinical statements about patient selection, nutrition, and side effect management for FLOT chemotherapy. The process involved multiple rounds of anonymous voting and feedback conducted virtually over six months in 2025. After each round, experts saw how others voted and could change their ratings based on new information. Consensus was defined as at least 7 out of 9 experts agreeing something was appropriate, or 1 to 3 experts agreeing it was inappropriate, with minimal disagreement among panelists.
The Delphi method is particularly useful for developing clinical guidance when strong research evidence is limited or when expert judgment is needed to translate research into practical recommendations. By keeping responses anonymous, the process prevents dominant personalities from influencing others and ensures each expert’s voice carries equal weight. The structured feedback rounds allow experts to reconsider their positions based on collective reasoning.
This approach builds on the RAND/UCLA Appropriateness Method, a well-established framework for creating clinical guidelines. The resulting consensus statements are designed to be practical and applicable across different healthcare systems worldwide, addressing real gaps in existing treatment guidelines.
FLOT is a proven, guideline-recommended treatment for stomach cancer, but doctors worldwide have lacked clear, agreed-upon standards for deciding which patients should receive it and how to manage it safely. This consensus fills that gap by providing evidence-based, expert-driven recommendations that can be applied in clinical practice. Having international agreement on these standards helps ensure patients receive consistent, high-quality care regardless of where they’re treated.
This study’s strength lies in its international expert panel and structured methodology designed to minimize bias. The anonymous voting process prevents any single expert from dominating the discussion. The 66.3% consensus rate on statements reflects genuine expert agreement on key issues, though the lower-than-typical consensus rate on some statements indicates areas where clinical judgment remains important. The main limitation is that this represents expert opinion rather than new research data, so recommendations should be considered alongside existing clinical evidence. The study was published in a peer-reviewed oncology journal, indicating it underwent expert review before publication.
What the Results Show
The expert panel reached strong consensus on several key patient selection criteria. Patients aged over 70 years should not be automatically excluded from FLOT treatment, but they do require comprehensive health assessment before starting. This is important because age alone should not determine treatment eligibility. The panel agreed that patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1, which measures how well patients can perform daily activities, are appropriate candidates. ECOG PS 0-2 may be considered on a case-by-case basis, meaning doctors can make individual decisions for patients with slightly lower functional status.
Before starting FLOT, the panel endorsed several preparatory steps. Adequate organ function (working kidneys, liver, and heart) must be confirmed through testing. Any baseline health conditions should be corrected before treatment begins. All patients should be screened for hepatitis B, and genetic testing for dihydropyrimidine dehydrogenase deficiency should be performed, as this genetic variation affects how the body processes one of the FLOT drugs.
Nutritional support emerged as a major theme in the consensus. Universal baseline nutritional screening for all patients was endorsed, meaning every patient should have their nutritional status assessed before treatment. Patients found to be malnourished should receive proactive nutritional intervention and support. Structured physical activity was also recommended as part of preparation for surgery and chemotherapy.
For managing side effects during treatment, the panel supported dose modification over drug omission when possible. This means if a patient experiences significant side effects, doctors should reduce the dose rather than skip doses entirely, preserving the treatment’s effectiveness while improving tolerability.
The panel also provided guidance on surgical planning and treatment timing. Multidisciplinary input from surgeons, oncologists, and other specialists was supported for surgical planning decisions. The consensus endorsed defined perioperative windows (specific timeframes for treatment before and after surgery), individualized dosing based on patient factors, and flexibility in the number of pre-operative and post-operative treatment cycles. This flexibility recognizes that not all patients follow the same treatment schedule and that individual circumstances should guide decisions.
FLOT has been established as a standard treatment for resectable gastric and gastroesophageal junction cancer based on major clinical trials. However, existing guidelines provided limited practical guidance on patient selection, nutritional optimization, and toxicity management. This consensus builds directly on current standards by addressing these specific gaps. The recommendations align with general oncology principles but provide stomach cancer-specific guidance that was previously unavailable in a coordinated, internationally agreed format.
This study represents expert consensus rather than new clinical trial data, so recommendations are based on collective experience and interpretation of existing evidence rather than new research findings. The panel included only 16 experts, which is relatively small, though they were selected for their international expertise and diverse specialties. The study did not evaluate whether following these recommendations actually improves patient outcomes, as that would require a separate clinical trial. Some statements did not reach consensus, indicating areas where expert opinion remains divided and clinical judgment is particularly important. The recommendations are most applicable to patients with resectable disease and may not apply to patients with advanced or metastatic gastric cancer.
The Bottom Line
If you have resectable gastric or gastroesophageal junction cancer, discuss FLOT treatment with your oncology team. These new guidelines support considering FLOT even if you’re over 70 years old, provided you have adequate organ function and overall health. Before starting treatment, ensure you receive nutritional screening and support, genetic testing for drug metabolism, and hepatitis B screening. Engage in physical activity as tolerated to prepare for surgery and chemotherapy. If side effects occur during treatment, work with your team to adjust doses rather than skip treatment entirely. These recommendations have high confidence among international experts but should be personalized to your individual situation.
These guidelines are most relevant for patients with resectable gastric cancer or gastroesophageal junction adenocarcinoma who are candidates for FLOT chemotherapy. Oncologists, surgeons, gastroenterologists, and other cancer care providers should use these recommendations when making treatment decisions. Patients and caregivers should be aware of these standards when discussing treatment options with their medical team. These guidelines are less applicable to patients with advanced metastatic disease or those who cannot tolerate chemotherapy.
FLOT treatment typically involves multiple cycles of chemotherapy given before surgery and sometimes after surgery. Each cycle usually lasts about two weeks, with the entire pre-operative course lasting several months. Patients may begin to experience side effects within days to weeks of starting treatment. Nutritional support should begin immediately before treatment starts. Physical benefits from structured activity may take several weeks to become apparent. Surgical recovery typically takes 4 to 8 weeks, with return to normal activities taking several months. Long-term outcomes and survival benefits may take years to fully evaluate.
Frequently Asked Questions
Can older patients with stomach cancer receive FLOT chemotherapy?
Yes, according to 2025 expert consensus, patients over 70 should not be automatically excluded from FLOT. However, they require comprehensive health evaluation including organ function tests, nutritional assessment, and genetic testing before treatment begins. Individual decisions depend on overall health status.
What tests should I have before starting FLOT treatment for gastric cancer?
The 2025 international expert consensus recommends organ function testing (kidney, liver, heart), hepatitis B screening, genetic testing for dihydropyrimidine dehydrogenase deficiency, and nutritional assessment. These tests ensure you can safely tolerate the treatment and identify any conditions needing correction first.
How important is nutrition before and during FLOT chemotherapy?
Universal nutritional screening and support are endorsed by the 2025 expert consensus as essential before FLOT treatment. Malnourished patients should receive proactive nutritional intervention. Good nutrition helps your body tolerate chemotherapy better and supports recovery before and after surgery.
What happens if I experience severe side effects from FLOT?
The 2025 expert consensus supports dose modification over skipping doses when side effects occur. This means your doctor can reduce the dose to improve tolerability while maintaining treatment effectiveness. Work closely with your oncology team to manage side effects rather than stopping treatment entirely.
Should I exercise before and during FLOT chemotherapy for stomach cancer?
Yes, the 2025 international expert consensus endorsed structured physical activity as part of treatment preparation and management. Physical activity helps maintain function, supports recovery, and may improve treatment tolerance. Discuss appropriate activity levels with your medical team based on your individual fitness.
Want to Apply This Research?
- Track weekly nutritional intake (calories, protein grams, and meals consumed), pre-treatment and during-treatment organ function test results, physical activity minutes per day, and any side effects experienced with severity ratings on a 1-10 scale.
- Use the app to schedule and log daily physical activity (walking, gentle exercise), set reminders for nutritional meals and supplements, record weekly weight and appetite changes, and document any side effects to discuss with your care team at appointments.
- Create a long-term tracking dashboard showing trends in nutritional status, physical function, treatment tolerance, and recovery milestones. Share weekly summaries with your oncology team to enable proactive management of any concerns and adjustment of treatment plans as needed.
This article summarizes expert consensus recommendations for FLOT chemotherapy in gastric and gastroesophageal junction cancer. These guidelines represent expert opinion based on existing evidence and should not replace individualized medical advice from your oncology team. Treatment decisions must be made in consultation with your physicians who understand your complete medical history, specific cancer characteristics, and individual health status. The recommendations in this article are intended for informational purposes and do not constitute medical advice. Always discuss any treatment options, concerns, or questions with your qualified healthcare providers before making medical decisions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.